

ASX Announcement (ASX: HLS)



ACN 064 530 516
REGISTERED OFFICE:
LEVEL 22
161 Castlereagh Street
SYDNEY NSW 2000
TEL: +61 2 9432 9400
FAX: +61 2 9432 9447

ASX Limited
Market Announcements Office
Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000

22 December 2023

Expiry of Unsolicited ACL Offer

Healius Limited (ASX:HLS) (**Healius**) notes that Australian Clinical Labs Limited (ASX:ACL) (**ACL**) has today announced that it has withdrawn its off market takeover offer for all of the fully paid ordinary shares on issue in Healius, the terms and conditions of which were set out in ACL's replacement bidder's statement dated 14 April 2023 (**Offer**).

As announced on 20 November 2023, the **156,148,077** Healius shares that were issued pursuant to Healius' recently completed non-renounceable entitlement offer (**New Shares**) have been trading in the separate quoted class 'HLSNB' on the basis that those New Shares were not subject to the Offer.

Now that the Offer has been withdrawn, those New Shares will:

- cease to be quoted in the 'HLSNB' class of shares at the close of trading on Friday, 22 December 2023; and
- be merged into the 'HLS' quoted class of Healius shares (together with all other Healius shares) from the commencement of trading on Wednesday, 27 December 2023.

ENDS

The release of this announcement has been authorised by the Company Secretary.

For further information contact:

Analysts and Market

Janet Payne
Group Executive, Corporate Affairs
Mobile: +61 409 995 517

Media

Andrew Butcher
Bespoke Approach
Mobile: +61 400 841 088

For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has two core diagnostics businesses, pathology and imaging. Through its unique footprint of centres and its 10,500 employees, Healius provides Australia-wide specialty diagnostic services to consumers and their referring practitioners.